Unnecessary — Issue 037
If a Shot Does the Discipline,
What Was the Discipline?
Appetite is a signal, not a character trait. The harder question is what you build while the signal is quiet.
Here is the uncomfortable question underneath the weight-loss drug boom. If a weekly injection can quiet the appetite that used to defeat you, what exactly was the discipline? Was it character, or was it a signal you had to white-knuckle through?← sit with this one
It matters because the numbers are now mainstream. A Gallup survey from late May and early June 2026 found about 11% of US adults currently taking a GLP-1 for weight loss, up from roughly 3% in 2024. A lot of people are living through this question in real time.
The useful answer is not moralistic in either direction. Appetite is a signal, and signals can be treated medically. What stays yours is everything the drug cannot do for you, which turns out to be most of the long game.
The Shot Works. That Is Not the Interesting Part.
Start with the plain fact: these drugs produce large weight loss in people who take them, which is why a bloc of the population adopted them in a couple of years. Gallup's polling also shows the US obesity rate falling from its 2022 peak of 39.9% to the mid-to-high 30s in 2026. Gallup's own text and table disagree slightly on the exact 2026 figure, so treat it as roughly a three-point drop and not a precise number.
The more useful question is what a man is actually buying. He is not buying fat loss. He is buying an appetite dial held at a lower setting by a drug that has to keep arriving to hold it there. That is the structure of a service, and the diagnostic this series uses on every service is to ask who holds the leverage on the day the payments stop.
None of this is an argument against using a medical tool when a doctor says it fits. It is an argument for reading the terms before signing, which is more than most funnels let you do.
What Happens When the Payments Stop
A 2026 systematic review and meta-regression in eClinicalMedicine pooled 48 studies, with its main regain model built on six randomised trials and 3,236 participants. It estimated that around 60% of the weight lost is regained within a year of stopping, with regain levelling off near 75% of the original loss. Fastest in the first months, slower after.
The authors are careful about the caveats, and so should we be. Most included studies carried moderate risk of bias, the model's data did not extend past 52 weeks so the longer-term figures are extrapolation, and a few studies showed no regain at all, though each had its own limits. The shape is still hard to ignore. For most people, the drug works while it is being taken and gives much of the result back afterward unless something else has been built in the meantime.
That is the access-versus-ownership diagnostic in its purest form. You had access to a lower weight. You did not own it.
The Part Nobody Puts in the Ad: Muscle
Weight is not the same thing as fat. When appetite is suppressed hard, calories and protein can fall together, and the body can pull energy from muscle as well as fat. Dietitians quoted in recent coverage describe it plainly: the drug does not attack muscle directly, but a big calorie and protein deficit can leave you losing lean tissue along with the fat.
That matters more for men past their early thirties, where muscle already declines with age, a decline commonly cited at around 1% a year. The practical advice from the clinicians quoted is consistent: strength train two or three times a week, eat protein deliberately across the day, avoid losing weight faster than your body can handle, and consider tracking body composition rather than only the scale. Heavy cardio alone is not the answer. A lighter man who has lost muscle has not necessarily become a healthier one.
Real Scarcity, Rented Scarcity, and the Price Tag
Run the diagnostic. Is the scarcity real? Appetite control used to be scarce and personal, and the new supply is a pharmaceutical one. That is genuine, but it is also a rented kind of scarcity, because the supplier controls price, availability and the terms. Prices have been moving fast. Novo Nordisk announced a $349 monthly cash price for Wegovy in late 2025, and the telehealth and compounding market that grew around these drugs has produced a thicket of offers of very uneven quality.
Price versus value is where the funnel gets slippery. A clinic that sells you a prescription plus a coaching subscription may be a legitimate care pathway or a recurring-revenue machine, and the difference is whether anyone is measuring what you keep. Ask what the plan is for the day you stop, who is checking for muscle loss, and what the total monthly cost is across the whole year. If the answers are vague, the product is the subscription, not the health.
The Quiet Status Game
There is a social layer here that nobody puts in the pharmacy leaflet. For years, a lean body was a visible signal: this man gets up early, says no to the second drink, runs the numbers on his life. Now the signal is noisier. Some of the men who look disciplined are medicated, and some of the men who look soft are simply on a different schedule. Gallup's figure that more than one in ten adults is on one of these drugs means the old read has stopped being reliable.
That is mostly healthy. A signal that can be rented was never a very good measure of character, and the status that came from it was always a little bit rented too. The harder, more durable status is the boring one: a man who can lift, who sleeps, who eats like he intends to be around, and who could do all of it with or without a prescription. That version can't be bought monthly, and that is exactly why it is worth having.
The honest advice to a man tempted by the shortcut is the same advice this series gives about watches, cars and everything else. Don't be ashamed of the tool. Be suspicious of anyone who tells you the tool is the whole job.
So What Was the Discipline?
Return to the opening question. The honest answer is that willpower never disappeared. It moved. When appetite is loud, discipline looks like refusing the second helping. When appetite is quiet, discipline looks like eating the protein you do not feel like eating, lifting on the days you could skip, and building the habits that will still be standing when the drug is not.
The men who do well on these drugs, on the available evidence and the clinicians' advice, treat the medication as a window and not a finish line. They use the window to build the thing they will own: training age, a protein habit, sleep, a relationship with food that does not depend on a prescription refill. The ones who treat the shot as the whole plan are the ones the regain data describes.
What a Sensible Man Does With This
Do not moralise it. Using a medically supervised drug is not a character flaw, and refusing one on principle is not a medal. Do not outsource the thinking to an app either. See an actual doctor, get baseline bloodwork and a body composition number, and ask about the exit plan on day one. Strength train from the first week. Hit a protein target. Track more than the scale. Budget the real cost over a year, not the teaser month. And decide now what you will do on the day the prescription ends, because that day is coming for most people, whether by choice, cost, side effects or supply.
This is general information, not medical advice. Your doctor knows your history; this column does not.
The House of Kong Take
Coming Up — Issue 038
The $1,000 phone. Flagship pricing keeps climbing while the real upgrades keep shrinking, and the upgrade cycle is the most successful subscription nobody calls a subscription. Next issue: price versus value, in your pocket.
